Vident Advisory LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Vident Advisory LLC increased its stake in Thermo Fisher Scientific by 23.5%, holding shares worth approximately $2.86 million after acquiring an additional 1,092 shares in the first quarter.
• Thermo Fisher Scientific's stock price has been raised by multiple analysts, with UBS Group increasing its target from $460 to $500 while maintaining a "neutral" rating.
• The company recently announced a quarterly dividend of $0.43 per share, payable on October 15, representing a 0.3% dividend yield.

Vident Advisory LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 23.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,738 shares of the medical research company's stock after buying an additional 1,092 shares during the period. Vident Advisory LLC's holdings in Thermo Fisher Scientific were worth $2,855,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares during the period. Nuveen LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $532,360,000. Farallon Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 73.8% during the 4th quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock valued at $641,577,000 after purchasing an additional 523,800 shares in the last quarter. Sarasin & Partners LLP purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $242,991,000. Finally, Two Sigma Advisers LP increased its holdings in shares of Thermo Fisher Scientific by 81.6% during the 4th quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock valued at $485,479,000 after purchasing an additional 419,200 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,666 shares of company stock valued at $13,982,763 in the last three months. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TMO. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Evercore ISI reduced their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research note on Friday, July 11th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $589.38.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $3.45 during mid-day trading on Wednesday, hitting $484.08. The stock had a trading volume of 1,213,169 shares, compared to its average volume of 1,729,669. The firm's 50 day moving average is $457.48 and its 200 day moving average is $453.94. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock has a market capitalization of $182.79 billion, a price-to-earnings ratio of 28.00, a PEG ratio of 2.63 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the company earned $5.37 EPS. The company's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.